Xenon Posts $1.11 Q2 Loss Per Share, Wider Than Expected
XENE sits 97% above its 52-week low of $32.78 on light trading volume (0.3× avg).
Summary
Xenon Pharmaceuticals reported a Q2 2026 net loss of $1.11 per share, a significant miss versus consensus expectations. The company's 8-K filed today confirms a net loss of $110.7 million, supported by $1.2 billion in cash. This follows a pattern of widening losses as R&D spending ramps ahead of key Phase 3 epilepsy data. The loss per share figure is the first concrete number from the quarter and will force analysts to revise models downward.
At the time of this announcement, XENE was trading at $64.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $32.78 to $72.66. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.